Poppy Seed Tea Latest Catch In FDA Enforcement Net For Opioid Claims
This article was originally published in The Rose Sheet
Executive Summary
PoppySeed Wash ‘medicinal’ beverage claiming to help ease opioid withdrawal and ease pain is an unapproved new drug and is misbranded, FDA says. Agency's warning is latest on supplements making opioid withdrawal claims, but the action has not prompted the Utah firm to discontinue selling its product online.
You may also be interested in...
Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue
FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.
Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI
FDA and the Federal Trade Commission should bring immediate enforcement action against marketers of non-kratom dietary supplements promoted as opioid-withdrawal aids, says the Center for Science in the Public Interest in letters to the agency and commission Dec. 8. The nonprofit identified eight supplement products making opioid-withdrawal claims without sufficient science to support the statements.
FDA Turns Kratom's Future In US Dietary Supplement Market Into History
FDA Commissioner Scott Gottlieb says kratom's apparently increasing use "as an alternative or adjunct to opioid use" has made enforcement on the ingredient more of a priority for FDA, and "given the scope of this crisis, we must do more."